Literature DB >> 19223478

Development of non-antibiotic-resistant, chromosomally based, constitutive and inducible expression systems for aroA-attenuated Salmonella enterica Serovar Typhimurium.

Jake N Matic1, Tamsin D Terry, David Van Bockel, Tracy Maddocks, David Tinworth, Michael P Jennings, Steven P Djordjevic, Mark J Walker.   

Abstract

Live-vaccine delivery systems expressing two model antigens from Mycoplasma hyopneumoniae, F2(P97) (Adh) and NrdF, were constructed using Salmonella enterica serovar Typhimurium aroA (STM-1), and immunogenicity in mice was evaluated. Recombinant plasmid-based expression (PBE) and chromosomally based expression (CBE) systems were constructed. The PBE system was formed by cloning both antigen genes into pJLA507 to create an operon downstream of temperature-inducible promoters. Constitutive CBE was achieved using a promoter-trapping technique whereby the promoterless operon was stably integrated into the chromosome of STM-1, and the expression of antigens was assessed. The chromosomal position of the operon was mapped in four clones. Inducible CBE was obtained by using the in vivo-induced sspA promoter and recombining the expression construct into aroD. Dual expression of the antigens was detected in all systems, with PBE producing much larger quantities of both antigens. The stability of antigen expression after in vivo passage was 100% for all CBE strains recovered. PBE and CBE strains were selected for comparison in a vaccination trial. The vaccine strains were delivered orally into mice, and significant systemic immunoglobulin M (IgM) and IgG responses against both antigens were detected among all CBE groups. No significant immune response was detected using PBE strains. Expression of recombinant antigens in S. enterica serovar Typhimurium aroA from chromosomally located strong promoters without the use of antibiotic resistance markers is a reliable and effective method of inducing a significant immune response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223478      PMCID: PMC2681777          DOI: 10.1128/IAI.01301-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  Impact of plasmid stability on oral DNA delivery by Salmonella enterica serovar Typhimurium.

Authors:  Michelle E Gahan; Diane E Webster; Steven L Wesselingh; Richard A Strugnell
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

2.  Mycoplasma arthritidis-derived superantigen (MAM) displays DNase activity.

Authors:  Markus Diedershagen; Silke Overbeck; Sabine Arlt; Birgit Plümäkers; Maria Lintges; Lothar Rink
Journal:  FEMS Immunol Med Microbiol       Date:  2007-03

Review 3.  Salmonella-based vaccines for infectious diseases.

Authors:  Young Min Kwon; Mandy M Cox; Leona N Calhoun
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

4.  Two domains within the Mycoplasma hyopneumoniae cilium adhesin bind heparin.

Authors:  Cheryl Jenkins; Jody L Wilton; F Chris Minion; Linda Falconer; Mark J Walker; Steven P Djordjevic
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

5.  Rational design of Salmonella-based vaccination strategies.

Authors:  Simone Spreng; Guido Dietrich; Gerald Weidinger
Journal:  Methods       Date:  2006-02       Impact factor: 3.608

6.  Glycogen phosphorylase, the product of the glgP Gene, catalyzes glycogen breakdown by removing glucose units from the nonreducing ends in Escherichia coli.

Authors:  Nora Alonso-Casajús; David Dauvillée; Alejandro Miguel Viale; Francisco José Muñoz; Edurne Baroja-Fernández; María Teresa Morán-Zorzano; Gustavo Eydallin; Steven Ball; Javier Pozueta-Romero
Journal:  J Bacteriol       Date:  2006-07       Impact factor: 3.490

7.  Use of the stationary phase inducible promoters, spv and dps, to drive heterologous antigen expression in Salmonella vaccine strains.

Authors:  D G Marshall; A Haque; R Fowler; G Del Guidice; C J Dorman; G Dougan; F Bowe
Journal:  Vaccine       Date:  2000-01-31       Impact factor: 3.641

8.  Evaluation of the immunogenicity of the P97R1 adhesin of Mycoplasma hyopneumoniae as a mucosal vaccine in mice.

Authors:  Austen Y Chen; Scott R Fry; Judy Forbes-Faulkner; Grant Daggard; T K S Mukkur
Journal:  J Med Microbiol       Date:  2006-07       Impact factor: 2.472

9.  Development of a nonantibiotic dominant marker for positively selecting expression plasmids in multivalent Salmonella vaccines.

Authors:  H V McNeill; K A Sinha; C E Hormaeche; J J Lee; C M Khan
Journal:  Appl Environ Microbiol       Date:  2000-03       Impact factor: 4.792

10.  Oral immunization of swine with attenuated Salmonella typhimurium aroA SL3261 expressing a recombinant antigen of Mycoplasma hyopneumoniae (NrdF) primes the immune system for a NrdF specific secretory IgA response in the lungs.

Authors:  P K Fagan; M J Walker; J Chin; G J Eamens; S P Djordjevic
Journal:  Microb Pathog       Date:  2001-02       Impact factor: 3.738

View more
  7 in total

1.  Sequence TTKF ↓ QE defines the site of proteolytic cleavage in Mhp683 protein, a novel glycosaminoglycan and cilium adhesin of Mycoplasma hyopneumoniae.

Authors:  Daniel R Bogema; Nichollas E Scott; Matthew P Padula; Jessica L Tacchi; Benjamin B A Raymond; Cheryl Jenkins; Stuart J Cordwell; F Chris Minion; Mark J Walker; Steven P Djordjevic
Journal:  J Biol Chem       Date:  2011-10-03       Impact factor: 5.157

2.  A vaccine candidate for post-weaning diarrhea in swine constructed with a live attenuated Salmonella delivering Escherichia coli K88ab, K88ac, FedA, and FedF fimbrial antigens and its immune responses in a murine model.

Authors:  Jin Hur; Barry D Stein; John Hwa Lee
Journal:  Can J Vet Res       Date:  2012-07       Impact factor: 1.310

3.  Evaluation of the humoral immune response in mice orally vaccinated with live recombinant attenuated Salmonella enterica delivering a secreted form of Yersinia pestis PsaA.

Authors:  Ascención Torres-Escobar; María Dolores Juárez-Rodríguez; Christine G Branger; Roy Curtiss
Journal:  Vaccine       Date:  2010-07-13       Impact factor: 3.641

4.  Enhancement of immune responses by an attenuated Salmonella enterica serovar Typhimurium strain secreting an Escherichia coli heat-labile enterotoxin B subunit protein as an adjuvant for a live Salmonella vaccine candidate.

Authors:  Jin Hur; John Hwa Lee
Journal:  Clin Vaccine Immunol       Date:  2010-12-15

5.  Comparative immunological evaluation of recombinant Salmonella Typhimurium strains expressing model antigens as live oral vaccines.

Authors:  Song-yue Zheng; Bin Yu; Ke Zhang; Min Chen; Yan-Hong Hua; Shuofeng Yuan; Rory M Watt; Bo-Jian Zheng; Kwok-Yung Yuen; Jian-Dong Huang
Journal:  BMC Immunol       Date:  2012-09-26       Impact factor: 3.615

6.  Predictable, Tunable Protein Production in Salmonella for Studying Host-Pathogen Interactions.

Authors:  Kendal G Cooper; Audrey Chong; Tregei Starr; Ciaran E Finn; Olivia Steele-Mortimer
Journal:  Front Cell Infect Microbiol       Date:  2017-11-16       Impact factor: 5.293

Review 7.  Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery.

Authors:  Ivan Y C Lin; Thi Thu Hao Van; Peter M Smooker
Journal:  Vaccines (Basel)       Date:  2015-11-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.